Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure [More]
New software-based method identifies patients with newly diagnosed HIV using EMRs

New software-based method identifies patients with newly diagnosed HIV using EMRs

A new, validated software-based method for identifying patients with newly diagnosed HIV using electronic medical records (EMRs) is described in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. [More]
Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan Inc. today announced that it has entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. [More]
"Expressive therapy" intervention helps HIV women, improves social support

"Expressive therapy" intervention helps HIV women, improves social support

New research from UC San Francisco shows that an "expressive therapy" group intervention conducted by The Medea Project helps women living with HIV disclose their health status and improves their social support, self-efficacy and the safety and quality of their relationships. [More]
HIV detected in Mississippi baby after apparent cure

HIV detected in Mississippi baby after apparent cure

In November 2013, it was reported that an infant (known as the “Mississippi baby”) had been in prolonged remission from HIV and was apparently cured. However, after 2 years without taking antiretroviral therapy and having no evidence of the virus, the child now has detectable levels of HIV. [More]
Mississippi baby: Infant seemingly cured of HIV has detectable levels of HIV

Mississippi baby: Infant seemingly cured of HIV has detectable levels of HIV

The child known as the "Mississippi baby"-an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall-now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case. [More]

Failure to provide adequate HIV services threatens global progress on HIV response, warns WHO

Failure to provide adequate HIV services for key groups - men who have sex with men, people in prison, people who inject drugs, sex workers and transgender people - threatens global progress on the HIV response, warns WHO. [More]
Mylan launches Telmisartan Tablets USP

Mylan launches Telmisartan Tablets USP

Mylan Inc. today announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis® Tablets. [More]
New meta-analysis highlights significant gaps in hepatitis C care

New meta-analysis highlights significant gaps in hepatitis C care

A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs. [More]
HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology. [More]
ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study. [More]
Study questions whether health system, government policies can meet needs of people aging with HIV

Study questions whether health system, government policies can meet needs of people aging with HIV

As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs. [More]
Study finds link between high CD4 cell counts and reduced ischemic stroke risk in people with HIV

Study finds link between high CD4 cell counts and reduced ischemic stroke risk in people with HIV

A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects. [More]
Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV). [More]
Mylan launches Risedronate Sodium Tablets USP, 150 mg

Mylan launches Risedronate Sodium Tablets USP, 150 mg

Mylan Inc. today announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. [More]
Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection. [More]
Researchers map transmission network of human immunodeficiency virus in San Diego

Researchers map transmission network of human immunodeficiency virus in San Diego

Researchers at the University of California, San Diego School of Medicine have mapped the transmission network of human immunodeficiency virus (HIV) in San Diego. [More]
Scientists identify new way to reactivate latent HIV

Scientists identify new way to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection. [More]